# PepGen Shares Rise 92.9% After Phase 2 Myotonic Dystrophy Results

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/53970
Published: 2026-11-11T12:54:08.000Z
Updated: 2026-11-11T12:54:08.000Z
Section: Business

> Six participants receiving 10 mg/kg had mean muscle RNA splicing correction of 46.5% at week 13. January extension data will cover clinical results at 5 mg/kg and safety at 10 mg/kg.

PepGen (NASDAQ: PEPG) shares rose 92.9% from Monday’s close to $4.61 at the Nov. 10 close after the company announced Phase 2 results for an experimental myotonic dystrophy treatment.

The FREEDOM2-DM1 study is evaluating PGN-EDODM1 for myotonic dystrophy type 1. Among six participants receiving 10 mg/kg, mean muscle RNA splicing correction reached 46.5% at week 13. Five participants had more than 20% correction, and four had more than 50%. A pooled placebo group of four participants from two dose cohorts averaged 6.8% correction.

At week 16, video hand-opening time, a measure of myotonia, improved by 3.9 seconds from baseline. The company also reported gains in hand grip strength, timed mobility and walking tests. Patient-reported measures were inconclusive at that point.

The 10 mg/kg cohort included eight participants: six assigned to PGN-EDODM1 and two to placebo. All eight completed the week 16 assessment. Treatment-emergent adverse events were mild or moderate; nausea was the most common. Four mild renal events occurred, along with transient albuminuria that declined with later doses. There were no severe or serious events, dose-limiting toxicities or treatment discontinuations.

The ongoing study is under a partial clinical hold in the United States, and no U.S. participants had been dosed. PepGen expects results from its fully enrolled 12.5 mg/kg cohort in the first half of 2027. Interim open-label extension data expected in January 2027 will include clinical data at 5 mg/kg and safety data at 10 mg/kg.